5 recruiting, 2 unknown, 1 completed, 1 not yet recruiting. 6 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Completed 1, Not yet recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Diffuse Large B Cell Lymphoma Refractory: new trials by email Literature Review of Diffuse Large B Cell Lymphoma Refractory trials Research Report on Diffuse Large B Cell Lymphoma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) VK-2019 - Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed | Phase 1 | Recruiting | Pierluigi Porcu | 30 | 2026-08-21 | 2026-09-02 |
| Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas Vancomycin 125mg, Radiation Therapy, CAR-T - Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL) | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 14 | 2026-05-29 | 2026-07-01 |
| Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas Glofitamab - Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Not yet recruiting | American University of Beirut Medical Center | 40 | 2026-04-15 | 2026-02-04 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies GF-CART01 - Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory | Phase 1 | Recruiting | GenomeFrontier Therapeutics TW Co., Ltd. | 18 | 2025-06-09 | 2026-06-12 |
| R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma R-DHAP, Pola-R-DHAP - Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2 | Withdrawn | Fondazione Italiana Linfomi - ETS | 2024-01-01 | 2024-05-21 | |
| Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL ZR2-ICE - Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-10-12 | 2024-03-13 |
| A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin - Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 41 | 2023-10-01 | 2024-06-25 |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma EZM0414 - Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Epizyme, Inc. | 13 | 2022-05-31 | 2025-06-22 |
| Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL Rituximab, Gemcitabine, Oxaliplatin - Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 1 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 12 | 2019-01-01 | 2019-02-15 |
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma Ibrutinib, DA-EPOCH-R, Lenalidomide - Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 35 | 2014-05-01 | 2019-02-05 |
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma (3) · Recurrence (3) · Lymphoma, Non-Hodgkin (2) · Epstein-Barr Virus Infections (1) · Infections (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma (4) · Lymphoma, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
Gemcitabine (2) · Lenalidomide (2) · Oxaliplatin (2) · Rituximab (2) · Dexamethasone (1) · Radiotherapy (1) · Vancomycin (1) · axicabtagene ciloleucel (1) · glofitamab (1) · ibrutinib (1)
Abramson Cancer Center at Penn Medicine (1) · American University of Beirut Medical Center (1) · Epizyme, Inc. (1) · Fondazione Italiana Linfomi - ETS (1) · GenomeFrontier Therapeutics TW Co., Ltd. (1) · Lyell Immunopharma, Inc. (1) · Pharmacyclics LLC. (1) · Pierluigi Porcu (1) · RenJi Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Zhejiang Cancer Hospital (1)
United States (5) · China (3) · Italy (1) · Taiwan (1)
Ali Bazarbachi, MD (1) · Elise Chong, MD (1) · Haiyan Yang (1) · Jutta Neuenburg, MD (1) · Monica Balzarotti, MD (1) · Pierluigi Porcu, MD (1) · Wei Xu, PhD& MD (1)
R01CA282411 (1)